213598-15-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloro-4-ethoxybenzoic acid 97 is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs and improve the efficacy of existing ones.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Chloro-4-ethoxybenzoic acid 97 serves as an intermediate in the production of various agrochemicals, helping to enhance crop protection and yield.
Used in Dye and Pigment Manufacturing:
3-Chloro-4-ethoxybenzoic acid 97 is utilized in the manufacturing of dyes and pigments, contributing to the creation of a wide range of colors and shades for various applications.
Used in Specialty Chemicals Production:
This chemical compound is also employed in the production of specialty chemicals, where its unique properties allow for the development of innovative and high-quality products for diverse industries.

InChI:InChI=1/C9H9ClO3/c1-2-13-8-4-3-6(9(11)12)5-7(8)10/h3-5H,2H2,1H3,(H,11,12)

Upstream product

• 192512-43-9 4-ethoxy-3-chloro-benzoic acid methyl ester 
• 99585-10-1 4-ethoxy-3-chloro-benzaldehyde 
• 473-34-7 N,N-dichloro-p-toluenesulfonamide 
• 619-86-3 4-(ethoxy)benzoic acid 

Downstream Products

• 1072947-86-4 ethyl 3-(5-{5-[3-chloro-4-(ethyloxy)phenyl]-1,2,4-oxadiazol-3-yl}-1H-indazol-1-yl)propanoate 
• 1417560-71-4 C₂₁H₁₆ClNO₂S 

Relevant academic research and scientific papers

S1P RECEPTORS MODULATORS

The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.

OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS

The present invention provides compounds of formula (I) or salts thereof, having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders mediated by S1P1 receptors.

Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity

Compounds of formula (I) and pharmaceutically acceptable salts and solvates: where R1is hydrogen, C1-6alkyl (optionally substituted by hydroxy or C1-4alkoxy), phenyl-C1-4alkyl-, C1-6alkenyl, C1-6

Substituted isoquinoline derivatives and their use as anticonvulsivants

This invention relates to novel substituted isoquinoline derivatives and their use as anticonvulsants.